print logo

Contact Our Offices

Clinical Trials

Reset Text Size: A A A

Retinal Vein Occlusion

Active Studies

SAPPHIRE (Clearside Biomedical)

A phase 3, 12 month, randomized, masked controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion.

SCORE2 Long Term Follow-Up Phase (NEI)

A multicenter, non-interventional extension study to understand the long-term efficacy and safety of anti-VEGF treatments on SCORE2 participants who completed the 12 month parent study.

Completed Studies

BRAVO (Genentech)

Phase 3 study of the efficacy and safety of ranibizumab (Lucentis) compared to sham injection in Branch Retinal Vein Occlusions.

COPERNICUS (Regeneron)

Phase 3 study of the safety, tolerability and biological effect of aflibercept (Eylea) for Central Retinal Vein Occlusions.

CRUISE (Genentech)

Phase 3 study of the efficacy and safety of ranibizumab (Lucentis) compared to sham injection in Central Retinal Vein Occlusions.

GENEVA (Allergan)

Phase 3 study of the efficacy of the Dexamethasone Intravitreal Implant (Ozurdex) in Retinal Vein Occlusions.

ICON (ICON Biosciences)

Phase 1 open label dose escalation study of the safety and tolerability of a sustained release Intravitreal Liquid Drug Delivery using Triamcinolone Acetonide.

NEWTON (NCRVA and Regeneron)

A 1 year Prospective study of Aflibercept (Eylea) for previously treated Macular Edema associated with Central Retinal Vein Occlusion.

SCORE2 (NEI)

A 1 year study of comparative treatment between bevacizumab (Avastin) and aflibercept (Eylea) for Retinal Vein Occlusion.

SHORE (Genentech)

Phase 4 study evaluating different dosing regimens of ranibizumab (Lucentis).

VIBRANT (Regeneron)

A 1 year, Phase 3 study of the efficacy, safety and tolerability of aflibercept (Eylea) compared to Laser for the treatment of Branch Retinal Vein Occlusion.